Cargando…

Ketanserin as potential additive drug to improve V/Q mismatch in COVID-19?

Detalles Bibliográficos
Autores principales: Kuindersma, M., Spronk, P. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453366/
https://www.ncbi.nlm.nih.gov/pubmed/32859243
http://dx.doi.org/10.1186/s13054-020-03257-y
_version_ 1783575342825340928
author Kuindersma, M.
Spronk, P. E.
author_facet Kuindersma, M.
Spronk, P. E.
author_sort Kuindersma, M.
collection PubMed
description
format Online
Article
Text
id pubmed-7453366
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74533662020-08-28 Ketanserin as potential additive drug to improve V/Q mismatch in COVID-19? Kuindersma, M. Spronk, P. E. Crit Care Letter BioMed Central 2020-08-28 /pmc/articles/PMC7453366/ /pubmed/32859243 http://dx.doi.org/10.1186/s13054-020-03257-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Letter
Kuindersma, M.
Spronk, P. E.
Ketanserin as potential additive drug to improve V/Q mismatch in COVID-19?
title Ketanserin as potential additive drug to improve V/Q mismatch in COVID-19?
title_full Ketanserin as potential additive drug to improve V/Q mismatch in COVID-19?
title_fullStr Ketanserin as potential additive drug to improve V/Q mismatch in COVID-19?
title_full_unstemmed Ketanserin as potential additive drug to improve V/Q mismatch in COVID-19?
title_short Ketanserin as potential additive drug to improve V/Q mismatch in COVID-19?
title_sort ketanserin as potential additive drug to improve v/q mismatch in covid-19?
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7453366/
https://www.ncbi.nlm.nih.gov/pubmed/32859243
http://dx.doi.org/10.1186/s13054-020-03257-y
work_keys_str_mv AT kuindersmam ketanserinaspotentialadditivedrugtoimprovevqmismatchincovid19
AT spronkpe ketanserinaspotentialadditivedrugtoimprovevqmismatchincovid19